School of Pharmacy, University of Birmingham, Birmingham, UK.
University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
J Oncol Pharm Pract. 2023 Jul;29(5):1083-1093. doi: 10.1177/10781552221090904. Epub 2022 Apr 11.
The availability of healthcare apps to support patient self-management of various medical conditions, including cancer, has increased considerably in the past decade. However, there are limited published data on the role of apps in the management of chronic myeloid leukaemia (CML). The primary aim of this study was to investigate the current and future role of apps as a means of supporting patients with CML.
A 31-item questionnaire was developed and distributed to patients via three on-line CML support groups.
Responses were received from 286 patients. There was an approximate 2:1 female: male split and the majority (54%, n = 155) resided in the United Kingdom. 91% (n = 260) of respondents were currently receiving drug treatment for their CML. 23.4% (n = 67) of respondents were aware that apps were available to support their CML management and 11.5% (n = 33) had experience of using such an app. 94.1% (n = 238) of those who had not used a patient support app in the past stated that they would consider using an app in the future to help manage their disease. App awareness was significantly higher amongst male patients (30.3% vs. 19.9%). Likelihood of being a current or previous app user was higher amongst younger patients (16.3% for <55 years old vs. 5.6% for ≥55 years old) whilst younger patients and those with a more recent diagnosis of CML were both more likely to be interested in using an app in the future. When asked about potential app functionality, a drug interaction checker was the feature of greatest interest to respondents.
We have identified both a lack of awareness of and a low uptake of patient support apps amongst CML patients. Importantly, we have demonstrated a clear interest in CML-specific apps amongst this population. Based on the functionality that study participants were most interested in, we will work with health care professionals, app developers and patients to develop a new app to deliver holistic support to CML patients.
在过去十年中，能够支持各种医疗状况（包括癌症）患者自我管理的医疗保健应用程序的可用性大大增加。然而，关于应用程序在慢性髓性白血病（CML）管理中的作用，发表的数据有限。本研究的主要目的是调查应用程序作为支持 CML 患者的手段的当前和未来作用。
开发了一个包含 31 个项目的问卷，并通过三个在线 CML 支持小组分发给患者。
收到了 286 名患者的回复。患者的男女比例约为 2:1（女性 54%，n=155，男性 46%，n=131），大多数（54%，n=155）居住在英国。91%（n=260）的患者正在接受治疗其 CML 的药物治疗。23.4%（n=67）的患者知道有支持 CML 管理的应用程序，11.5%（n=33）有使用此类应用程序的经验。94.1%（n=238）过去没有使用过患者支持应用程序的患者表示，他们将来会考虑使用应用程序来帮助管理他们的疾病。男性患者的应用程序意识明显更高（30.3%对 19.9%）。年轻患者（55 岁以下的患者为 16.3%，55 岁以上的患者为 5.6%）成为当前或过去应用程序用户的可能性更高，而年轻患者和 CML 诊断时间较短的患者都更有可能将来使用应用程序。当被问及潜在的应用程序功能时，药物相互作用检查器是受访者最感兴趣的功能。
我们发现 CML 患者对患者支持应用程序的认识不足且使用率低。重要的是，我们在这一人群中发现了对 CML 特定应用程序的明确兴趣。基于研究参与者最感兴趣的功能，我们将与医疗保健专业人员、应用程序开发人员和患者合作，开发一款新的应用程序，为 CML 患者提供全面支持。
